Successful transplantation depends on more than placing cells in the retina: the introduced RPE must survive and integrate beneath the photoreceptor layer. In that position, the cells can potentially re-establish local support functions, including maintenance of the blood-retina barrier, photoreceptor metabolic support, and removal of shed outer segments. These location-dependent functions make tissue integration a central biological endpoint.
Immune compatibility matters because transplanted cells interact with the recipient’s retinal environment rather than functioning in isolation. Research therefore examines whether the graft remains viable and compatible with surrounding tissue while carrying out RPE-associated support roles. Poor compatibility could limit persistence and integration, making it difficult to determine whether any change in retinal or visual function results from the intended cell replacement.
Successful integration should be evaluated as both a positional and functional outcome. The hESC-derived RPE cells need to remain beneath the photoreceptor layer and contribute to the local retinal environment. Relevant functions include maintaining the blood-retina barrier, supporting photoreceptor metabolism, and phagocytosing shed outer segments. Together, these criteria indicate whether the graft provides meaningful biological support rather than merely remaining present.
After delivery, evaluation follows several linked questions: do the hESC-derived RPE cells survive, do they integrate beneath the photoreceptor layer, and do they remain compatible with the surrounding retinal environment? Researchers then consider whether these cellular outcomes preserve or improve visual function. This sequence connects a transplantation event to tissue-level biology and ultimately to the functional outcome of interest.
The main disease context is retinal degeneration associated with RPE dysfunction and progressive vision loss. In these settings, investigators ask whether supplying replacement RPE can preserve retinal support or contribute to improved function after tissue damage. The approach is therefore studied as a regenerative strategy, while its effectiveness remains an experimental research question rather than an established treatment outcome.
Visual function is a downstream measure, not the only evidence of success. A study also needs to establish whether transplanted cells survive, occupy the intended retinal location, integrate with tissue, and remain immunologically compatible. Interpreting functional results alongside these cellular and tissue findings helps connect vision-related changes to the biology of the graft rather than treating vision alone as proof of successful replacement.